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ANNOTATION
Preventive and therapeutic measures introduced and accepted because of
their favorable influences in altering the incidence or outcome of specific
health problems are likely to have more far-reaching effects than originally
envisioned or immediately observed. One unanticipated result may be the
emergence, either directly or indirectly, of another disease. The association
is often obscure because the related events are infrequent, scattered in
time and place, or separated by long and irregular intervals. An example
is provided by the delayed and sporadic occurrence, of hepatitis which
may follow in the wake of effective therapeutic and preventive uses of
blood and blood products.
Parenteral transmission of hepatitis viruses probably existed at a
low and unrecognized level long before organized vaccination programs
and treatment clinics of the late nineteenth and early twentieth centuries
afforded appropriate mechanisms for producing large numbers of such
infections in limited temporal and spatial settings. Even then an under-
standing of the etiology evolved rather slowly. Sufficient evidence was
available by 1938 to lead Findlay and MacCallum' to conclude that this
form of hepatitis, clinically indistinguishable from infectious hepatitis,
was transmitted through the medium of human serum or plasma, and
that the etiologic agent was almost certain to be a virus that could be
present in the sera of "apparently healthy persons who (had) never
knowingly suffered from jaundice." These conclusions were substantiated
during the next several years by detailed analyses of several epidemics.
Among them was one' with which Dr. Beeson was directly concerned as
a member of the American Red Cross-Harvard Field Hospital Unit in
England. This experience undoubtedly led, soon after his return to the
United States, to his search for and description of "cases of jaundice
which occurred one to four months after transfusions of whole blood or
plasma."' This was the first published report that clearly implicated whole
blood in hepatitis transmission and pointed to the probability that the
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association was not an unusual one. It also provided evidence that both
the shorter incubation infectious hepatitis and longer incubation serum
hepatitis (homologous serum jaundice) were transmissable by the paren-
teral route. Confirmatory reports soon appeared. By the mid-1940's hepatitis
had been established as one of the major hazards associated with the
rapidly increasing use of whole blood, plasma, and certain plasma protein
fractions.
The immense popularity of pooled plasma preparations as blood volume
expanders following World War II provided ample evidence of the seem-
ingly ubiquitous presence of hepatitis virus carriers among large donor
populations. For almost a decade the risk of "homologous serum jaun-
dice" following the use of plasma was of such a magnitude that the
contribution of whole blood to the over-all problem was somewhat obscured.
The failure of ultraviolet irradiation' to render plasma noninfectious, the
development of safer substitutes, and the increasing availability of whole
blood through organized regional collecting programs subsequenly led to a
marked decrease in the clinical use of plasma and a decline in its relative
importance in hepatitis transmission. For the period 1963-64, plasma alone
accounted for less than two per cent and blood alone for more than 90
per cent of all reported hepatitis following transfusion of blood and blood
products.! Mosley has recently noted an association between changing
patterns of plasma and whole blood usage and a shift in the distribution of
reported incubation periods. This suggests that the more commonly ob-
served long incubation period serum hepatitis of the 1940's is giving way
to intermediate and shorter incubation period infectious hepatitis. In any
large series of cases among patients who have received only blood the
incubation periods are distributed over a wide range, from less than one
to five or more months, covering the spans for both infectious and serum
hepatitis. However, the inclusive term "post-transfusion hepatitis," which
avoids but does not diminish the desirability for the epidemiologic differen-
tiation between IH and SH, has merit as a diagnostic label because it
places emphasis on the mode of transmission.
The observed frequency of hepatitis following transfusion varies widely
in reports published by different investigators using different study methods
at different times in different areas, but the average rate for the United
States appears to be in the range of five cases of icteric hepatitis per
1,000 units of blood. Whether or not the rate has changed appreciably
over the past twenty years is a matter of speculation; there can be little
doubt that the magnitude of the problem has increased. Accurate data for
the general direct patient use of whole blood during this period are un-
soo
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available, but records of long-established blood banking facilities may
serve as a reliable guide to the trends. The average number of units
processed each year by the Blood Bank of the Yale-New Haven Hospital
has increased six-fold from the early 1940's to the mid-1960's.7 For the
United States, it has been estimated that in 1963 1.8 million patients
received approximately 6.0 million units of blood8 which could have been
expected to result in 30,000 cases of hepatitis,9 a staggering figure when
compared with the 537 cases officially reported to the Communicable
Disease Center for the year beginning July, 1963.V Evenx so, it may
represent a gross underestimate of the true frequency of transmission.
Anicteric and asymptomatic infections, long recognized as epidemiol-
ogically and clinically important components of the total picture of infec-
tious hepatitis in epidemic situations, have been late to receive serious
attention as potentially important elements of post-transfusion hepatitis.
Shimizu and Kitamoto10 carefully observed 175 surgical patients in Tokyo
hospitals for at least 90 days following multiple small (200 ml.) trans-
fusions. Only ten (6 per cent) of the patients developed frank icterus, but
113 (64 per cent) developed sustained elevations of serum transaminase
levels indicative of hepatitis. The frequency of hepatitis was directly
related to the amount of blood received. The over-all rate was 59 cases
per 1,000 units, with a 10:1 ratio of anicteric to icteric infections. In a
somewhat similar study, Hampers, Prager, and Senior11 followed a group
of 56 blood recipients and 25 nontransfused patients from the same hospital
population in Philadelphia. No cases of icteric hepatitis were observed
in either group, but ten (18 per cent) of the transfused patients developed
evidence of anicteric hepatitis, a rate of 87 cases per 1,000 units. By
comparison with retrospectively calculated local rates for icteric post-
transfusions hepatitis, the authors suggested that over 100 anicteric in-
fections may occur for each recognized icteric case. Although extrapolation
based on these limited studies is hazardous, it would appear justified
to assume that the rate of hepatitis virus transmission is far in excess of all
previous estimates. The true frequency can be determined only when appro-
priate specific virologic and serologic techniques become available.
Progress in hepatitis virology, in the identification of carriers among
blood donors, and in the search for effective preventive measures has been
agonizingly slow in an era marked by rapid advances in the laboratory and
preventive aspects of many other viral infections. Still undetectable in
blood by any means other than the long delayed clinical response of the
recipients, the hepatitis viruses present an unpredictable risk associated
with each individual transfusion episode. Of necessity the risk is accepted,
501YALE JOURNAL OF BIOLOGY AND MEDICINE
albeit reluctantly, by blood banks and physicians and usually unknowingly
by patients. Since physical and chemical methods for sterilization of blood
without significant alteration of its component parts have not proved
feasible, major efforts at reducing transmission have been directed toward
donor selection.
Prolonged viremia during the incubation periods of both infectious
and serum hepatitis has dictated the practice of excluding donors with
admitted histories of known exposure to possible infection with either
virus within appropriate intervals. Blood from otherwise healthy donors
with a past history of hepatitis or unexplained jaundice is usually rejected
or reserved for fractionation even though there is meagre evidence, except
for the study of Matthes and Riderer,u that such blood carries an increased
risk. In reviewing reported studies of probable and proven hepatitis carriers,
a history of past jaundice appears infrequently although alcoholism and
cirrhosis are not uncommon, findings consistent with the increased risk
of hepatitis associated with blood purchased from professional donors.'1
The growth of organized blood collections from voluntary donors has un-
doubtedly served to reduce the risk, but present donor selection practices
alone cannot be expected to eliminate it, especially in view of the in-
efficiency of follow-up and case reporting which are essential to the
identification of "silent" and possibly intermittent carriers.
The effectiveness of gamma globulin in attenuating the clinical features
of post-transfusion (primarily long incubation) hepatitis became a matter
of controversy in the late 1940's when two large, but not strictly comparable
studies'X produced seemingly contradictory findings. The subject ap-
peared to be settled by the negative results of experimental trials in
which volunteers inoculated with known infectious serum received either
large doses of regular pooled gamma globulin or much smaller doses of
experimentally obtained "hyperimmune" gamma globulin.""' Recently the
question wes reopened when the results of a large controlled clinical trial
revealed a reduction of approximately 70 per cent in the expected in-
cidence of icteric hepatitis among the gamma globulin-treated group.'9
Dawson' has reported comparable findings. In both of these trials the
gamma globulin dosage (10 ml. during the first week following trans-
fusion and 10 ml. one month later) was similar to that employed in the
original study of Grossman, et al.' Grady9 has found much smaller doses
(2.0 to 5.0 ml.) to be ineffective.
The most one can expect of gamma globulin is the suppression of a
clinical response, not prevention of infection. The over-all case fatality
rate for post-transfusion hepatitis with jaundice is approximately 10
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per cent, a figure which is influenced to some degree by the nature of
the underlying conditions for which transfusions are given. Deaths due
to anicteric forms of post-transfusion hepatitis are either rare or un-
recognized. The possible long-term effects of such infections remain
speculative. Until effective methods are devised for the prevention of
infection, the conversion by gamma globulin of an icteric and potentially
fatal response to an anicteric one would appear to be a justified and logical
intermediate goal. At the present time, however, the controversy of twenty
years ago is far from settled and there are doubts about the ready avail-
ability of sufficient gamma globulin to "protect" all transfusion and plasma
protein recipients. The contradictory findings are likely to be due to
variables that can be assessed only by further well-controlled clinical
trials currently under way or planned for the near future.
REFERENCS
1. Findlay, G. M. and MacCallum, F. O.: Hepatitis and jaundice associated with
immunization against certain virus diseases. Proc. roy. Soc. Med., 1938, 31,
799-805.
2. Beeson, P. B., Chesney, G., and McFarlan, A. M.: Hepatitis following injection
of mumps convalescent plasma. Lancet, 1944, 1, 814-815.
3. Beeson, P. B.: Jaundice occurring one to four months after transfusion of blood
or plasma. J. Amer. med. Ass., 1943, 121, 1332-1334.
4. James, George, Korns, R. F., and Wright, A. W.: Homologous serum jaundice
associated with the use of irradiated plasma. J. Amer. med. Ass., 1950, 144,
228-229.
5. Hepatitis Surveillance Report No. 21, Communicable Disease Center, U.S. Public
Health Service, Atlanta, Georgia, December 31, 1964.
6. Mosley, J. W.: New patterns of transfusion-associated hepatitis. Presented at the
meeting of the American College of Physicians on October 8, 1965, Miami,
Florida.
7. Bove, J. R.: Personal communication.
8. Gibson, S. T.: Serum hepatitis. (Letter to the Editor.) J. Amer. med. Ass.,
1963, 186, 272.
9. Grady, George F.: Personal communication.
10. Shimizu, Y. and Kitamoto, O.: The incidence of viral hepatitis after blood
transfusions. Gastroenterology, 1963, 44, 740-744.
11. Hampers, C. L., Prager, D., and Senior, J. R.: Post-transfusion anicteric hepa-
titis. New Engl. J. Med., 1964, 271, 747-754.
12. Matthes, Max and Riderer, Ursula: Wie lange Zeit sollen Blutspender nach
einer Hepatitis von Blutentnahmen ausgeschlossen werden? Dtsch. mcd.
Wschr., 1956, 81, 1914-1917.
13. Allen, J. G. and Sayman, W. A.: Serum hepatitis from transfusions of blood:
epidemiologic study. J. Amer. med. Ass., 1962, 180, 1079-1085.
14. Grady, G. F. and Chalmers, T. C.: Risk of post-transfusion hepatitis. New
Engl. J. Med., 1964, 271, 337-342.
15. Grossman, E. B., Stewart, S. G., and Stokes, Joseph, Jr.: Post-transfusion
hepatitis in battle casualties and a study of its prophylaxis by means of
human immune serum globulin. J. Amer. med. Ass., 1945, 129, 991-994.
503TALE JOURNAL OF BIOLOGY AND MEDICINE Volume 38, June, 1966
16. Duncan, G. G., Christian, H. A., Stokes, Joseph, Jr., Rexer, W. F., Nicholson,
J. T., and Edgar, A.: An evaluation of immune serum globulin as a prophy-
lactic agent against homologous serum hepatitis. Amer. J. med. Sci., 1947,
213, 53-57.
17. Stokes, Joseph, Jr., Blanchard, Mercer, Neefe, J. R., Gellis, S. S., and Wade,
G. R.: Methods of protection against homologous serum hepatitis. J. Amer.
med. Ass., 1948, 138, 336-341.
18. Drake, M. E., Barondess, J. A., Bashe, W. J., Jr., Henle, Gertrude, Henle,
Werner, Stokes, Joseph, Jr., and Pennell, R. B.: Failure of convalescent
gamma globulin to protect against homologous serum hepatitis. J. Amer.
med. Ass., 1953, 152, 690-693.
19. Mirick, G. S., Ward, Robert, and McCollum, R. W.: Modification of post-trans-
fusion hepatitis by gamma globulin. New Engi. J. Med., 1965, 273, 59-65.
20. Dawson, D.: A clinical study on the use of immune globulin prophylaxis in
patients receiving blood and/or plasma transfusions. Curr. ther. Res., 1965,
7, 184-186.
504